Lunsumio
Active Ingredient: Mosunetuzumab-axgb
Brand: Lunsumio
Origin: USA
LUNSUMIO (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if LUNSUMIO is safe and effective in children.
Disclaimer
At WPI Pharma, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. It is not exhaustive and may not cover all medical conditions, treatments, or precautions. Always consult a qualified healthcare professional regarding any medical concerns. Do not ignore or delay seeking medical advice based on information provided here.
All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer / TM Owner" section in compliance with statutory requirements.
By continuing to access or use this website, you acknowledge and agree to the terms set forth herein. If you do not consent to these terms, you are advised to discontinue browsing immediately. Should you identify any inaccuracy, infringement, or other concern, you are encouraged to promptly report the matter for review and appropriate action. If you wish to request the removal of a product or any part of its content, please contact us at legal@wpipharmaceuticals.com.